Skip to Content

Arch Biopartners Inc

Rating as of

Company Profile

Business Description

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. Its under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

27 St. Clair Avenue East, P.O. Box 305
Toronto, ON, M4T 2M5, Canada
T +1 647 428-7031
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Sep 30, 2020
Stock Type